# NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/nf106-a-neurofibromatosis-clinical-trials-consortium-phase-ii-trial-of-the-mek/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Brian Weiss,Pamela L. Wolters,Scott R. Plotkin,Brigitte C. Widemann,James H. Tonsgard,Jaishri O. Blakeley,Jeffrey C. Allen,Elizabeth K. Schorry,Bruce R. Korf,Nathan Robison,Stewart Goldman,Alexander A. Vinks,Chie Emoto,Tsuyoshi Fukuda,Coretta Thomas Robinson,Gary Cutter,Lloyd J. Edwards,Eva Dombi,Nancy Ratner,Roger J. Packer,Michael J. Fisher |
| Citations | 155 |
| DOI | 10.1200/jco.20.02220 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.02220 |
| OpenAlex ID | https://openalex.org/W3123814388 |
| PMID | 33507822 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Brigitte C. Widemann](https://scholariq.org/researchers/brigitte-c-widemann/)
- [Gary Cutter](https://scholariq.org/researchers/gary-cutter/)
- [Pamela L. Wolters](https://scholariq.org/researchers/pamela-l-wolters/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Neurofibromatosis and Schwannoma Cases](https://scholariq.org/topics/neurofibromatosis-and-schwannoma-cases/)

## Paper topics

- [Neurofibromatosis and Schwannoma Cases](https://scholariq.org/topics/neurofibromatosis-and-schwannoma-cases/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Meningioma and schwannoma management](https://scholariq.org/topics/meningioma-and-schwannoma-management/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.